Medicine and Dentistry
Acute Leukemia
100%
Acute Myelogenous Leukemia
100%
Adverse Event
100%
Anemia
50%
Atrial Flutter
50%
Catenin
50%
Decreased Appetite
50%
Febrile Neutropenia
50%
Glycogen Synthase Kinase
50%
Glycogen Synthase Kinase 3 Inhibitor
100%
Isoprenaline
100%
Nausea
50%
Pharmacokinetics
50%
QT Prolongation
50%
Ranitidine
50%
Thrombocytopenia
50%
Vision Disorder
50%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Leukemia
100%
Adverse Event
100%
Anemia
50%
Catenin
50%
Decreased Appetite
50%
Febrile Neutropenia
50%
Glycogen Synthase Kinase
50%
Glycogen Synthase Kinase 3 Inhibitor
100%
Heart Atrium Flutter
50%
Isoprenaline
100%
Nausea
50%
Pharmacokinetics
50%
QT Prolongation
50%
Ranitidine
50%
Remission
50%
Thrombocytopenia
50%
Visual Disorder
50%
Keyphrases
Acceptable Safety
25%
Acute Leukemia
100%
Anemia
25%
Atrial Flutter
25%
Catenin
25%
Clinical Benefit
25%
Clinically Significant
25%
Complete Remission
25%
Decreased Appetite
25%
Dose Rate
25%
Drug Dependence
25%
Febrile Neutropenia
25%
Glycogen Synthase kinase-3 Inhibitors
100%
GSK-3 Inhibitors
25%
Hematologic
25%
LY2090314
100%
Nausea
25%
Nonhematologic
25%
On-target Effects
25%
Partial Remission
25%
Pharmacokinetics
25%
Phase 1 Study
25%
Phase II Study
100%
QT Prolongation
25%
Ranitidine
25%
Thrombocytopenia
25%
Treatment-related Adverse Events
50%
Visual Disturbance
25%
Neuroscience
Atrial Flutter
50%
Catenin
50%
Glycogen Synthase Kinase 3 Inhibitor
100%
GSK-3
50%
Isoprenaline
100%
Pharmacokinetics
50%
QT Interval
50%
Ranitidine
50%